Population dynamics modeling of split^50cM <i>ClvR</i> V1 introduced at a 50% release, with fitness cost per allele varying from 0–15%. by Georg Oberhofer (3401438)

Administration of anti-CD25 antibody decreases the early and late organ fungal burdens of resistant and susceptible mice. by Maíra Felonato (296591)

Exercise testing criteria to diagnose lower extremity peripheral artery disease assessed by computed-tomography angiography by O. Stivalet (6890189)

“…In the subset of patients with an ABI >0.91, cut-off values of post-exercise ABI decrease (AUC = 0.67[0.53–0.78]), and DROP (AUC = 0.67[0.53–0.78]) were ≥18.5%, and ≤-15mmHg respectively (p<0.05).…”

Change of oxygen concentration at each measuring point. by Yun Qi (560401)

Change of the switch point between dual-E and single-E control with decreasing values of <i>k</i>₉, <i>k</i>₁₁, and <i>k</i>₁₃. by Qaiser Waheed (5095328)

Phlorizin decreased renal GTTR uptake, and increased serum drug levels <i>in vivo</i>. by Meiyan Jiang (438439)

Results of comparison between Model5 and Model9. by Taiga Mori (21410076)

Results of comparison between Model5 and Model10. by Taiga Mori (21410076)

Serotype-specific penicillin non-susceptibility during different PCV periods in Iceland, Romania, Spain and Belgium [68, 69, 76, 78, 84, 85]. by Heloisa Ricci Conesa (18291210)

Subjects:

Procedures of sampling and measurements. by Xuegang Mao (599968)

Subjects:

Introduction status of PCVs in European countries over time. by Heloisa Ricci Conesa (18291210)

Subjects:

Data extraction grid. by Heloisa Ricci Conesa (18291210)

Subjects:

Incidence rates of AOM cases. by Heloisa Ricci Conesa (18291210)

Subjects:

Inclusion criteria. by Heloisa Ricci Conesa (18291210)

Subjects:

PRISMA flow diagram for the literature search. by Heloisa Ricci Conesa (18291210)

Subjects:

Estimates for direct medical and total costs per AOM episode (2020 EUR), by country [35, 96–100]. by Heloisa Ricci Conesa (18291210)

Subjects:

Vertical distributions in the three field settings. by Xuegang Mao (599968)

Subjects:

Fig 5 - by Kellie J. Walters (10451329)

Subjects:

<i>prx-5/6</i> mutations likely cause a decrease in mmBCFA degradation. by Rencheng Wang (463927)

“…<i>elo-5</i>(<i>lf</i>)<i>; Ex</i>[<i>elo-6</i>] is a transgenic strain that significantly overexpressed the <i>elo-6</i> gene and was not sufficient to suppress the L1 arrest phenotype of <i>elo-5</i>(<i>lf</i>). …”

HAstV-1 infection leads to a decrease in epithelial markers while increasing mesenchymal markers. by Virginia Hargest (12447014)